Teva bids up to $125m for BioXcel neuroscience assets in bankruptcy auction

A stalking horse bid of up to $125m puts Teva Pharmaceuticals International (TEVA) ahead of the queue to acquire BioXcel Therapeutics' core neuroscience assets, with the outcome pending a Section 363 court-supervised auction in the US Bankruptcy Court for the District of Delaware. The deal targets worldwide rights to Igalmi, a commercially available dexmedetomidine sublingual film, and investigational BXCL501, currently before the FDA. The next confirmable step is the auction result.

The bid structure

Teva's offer carries $57.5m upfront, with up to $67.5m in contingent payments linked to FDA approval timing and specified sales milestones, per the agreement. The conditional portion means the $125m ceiling is not guaranteed; those payments remain tied to regulatory and commercial outcomes that have not yet materialized.

BioXcel Therapeutics entered voluntary Chapter 11 proceedings to facilitate a court-supervised sale of substantially all its assets, with the company citing the goal of maximizing stakeholder value. To sustain operations through the process, BioXcel has secured $19m in debtor-in-possession financing from existing lenders.

The stalking horse structure works in Teva's favor if no competing bid emerges. Should Teva not prevail at auction, the agreement provides for a break-up fee and reimbursement of certain expenses. Igalmi remains commercially available during the proceedings.

The assets and the regulatory line

Igalmi is already generating commercial activity as a prescription sublingual film. BXCL501 is the more speculative piece of the transaction. The FDA is currently reviewing it for potential at-home use in treating acute agitation associated with schizophrenia or bipolar I or II disorder in adults. That review has not concluded, so revenue tied to BXCL501 approval sits squarely on the conditional side of the $67.5m in contingent consideration.

Evan Lippman, Teva's executive vice-president of business development, described the move as consistent with the company's "Pivot to Growth strategy," adding that it reflects a disciplined approach to assets with a clear strategic fit and long-term growth potential while balancing risk and value creation.

The Section 363 auction determines whether Teva secures the assets or walks with its break-up fee. Watch for the bankruptcy court's auction schedule and any competing bids that would reset the floor Teva has established.